Belite Bio (BLTE) Earnings Date & Reports

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

BLTE is expected to report earnings to rise 15.63% to -37 cents per share on May 07

Q1'25

Est.

$-0.37

Q4'24

Est.

$-0.32

Q3'24

Beat

by $0.01

Q2'24

Missed

by $0.05

Q1'24

Beat

by $0.01

The last earnings report on March 17 showed earnings per share of -31 cents, meeting the estimate of -31 cents. With 17.21K shares outstanding, the current market capitalization sits at 2.16B.

View a ticker or compare two or three

Compare

BLTE